[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627420":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":38,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":7,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":64,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Caja Costarricense de Seguro Social","OTHER_GOV",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Guselkumab (GUS)","Psoriatic disease, including psoriasis and psoriatic arthritis, is a chronic immune-mediated inflammatory condition with substantial clinical and quality-of-life impact. Several biologic classes are available for moderate-to-severe disease, including TNF-α inhibitors, IL-17 inhibitors, and IL-12\u002F23 inhibitors. IL-23-specific inhibitors (guselkumab and risankizumab) selectively block the p19 subunit of IL-23, providing targeted suppression of the Th17 pathway while preserving IL-12-dependent immune responses. This mechanism distinguishes them from IL-12\u002F23 inhibitors (p40 blockade) and IL-17 inhibitors (downstream cytokine inhibition).\n\nIL-23 inhibitors also differ in dosing interval (every 8-12 weeks) and safety profile, with lower candidiasis risk than IL-17 blockade and different infection patterns than TNF-α inhibitors. This national registry specifically evaluates real-world effectiveness, safety, and treatment persistence of IL-23 inhibitors.",{"type":10,"name":14,"description":12,"armGroupLabels":7,"otherNames":7},"Risankizumab (RISA)",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Daniel E Barquero-Orias, Dermatologist","CONTACT","+506 8341026","debarque@ccss.sa.cr",[22],{"facility":23,"status":7,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Caja Costarricense del Seguro Social","San José","Provincia de San José","40901","Costa Rica","CR",{"type":30,"coordinates":31},"Point",[32,33],-84.08489,9.93388,{"lat":33,"lon":32},[36],{"name":17,"role":18,"phone":37,"phoneExt":7,"email":20},"+506 83411026",{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Daniel Barquero Orias","Principal Investigator","100627420","costa-rican-registry-of-il-23-inhibitors-in-psoriatic-disease-100627420",false,"NCT07448402","Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of psoriatic disease, including psoriasis (any clinical variant) and\u002For psoriatic arthritis based on rheumatologic criteria.\n* Receiving IL-23 inhibitor therapy (guselkumab or risankizumab).\n* Treated within participating Costa Rican public health centers.\n* Availability of sufficient clinical records to complete registry data (history, follow-up, labs).\n* Age ≥12 years, any sex.\n\nExclusion Criteria:\n\n* None specified (all patients meeting inclusion criteria are eligible).","ALL","12 Years",{"count":52,"type":53},50,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and\u002For psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:\n\n* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?\n* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?\n* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA\u002FBASDAI) and adverse-event reporting through a national registry.",[58,59,60],"Psoriasis","Psoriasis Arthritis","Psoriasis (PsO)",[58,62,63,27],"IL-23","Registry","NOT_YET_RECRUITING","2026-03-06",{"date":67,"type":68},"2026-03-09","ACTUAL",{"date":70,"type":53},"2026-05",{"date":72,"type":53},"2031-05",{"name":5,"class":6},1]